The Boundary of End-of-Life Self-Determination -Comparative Analysis of South Korea’s Life-Sustaining Treatment Decision Act and the Assisted Death Pathways in the UK, Isle of Man, and Canada-

Abstract

Rapid population aging and the growing salience of end-of-life (EOL) suffering have sharpened attention to the legal boundary between foregoing life-sustaining treatment and physician-facilitated death. Using comparative doctrinal and normative analysis, the discussion contrasts South Korea’s Life-Sustaining Treatment Decision Act with evolving assisted-dying pathways in England & Wales, the Isle of Man, and Canada. Korea’s framework, enacted in 2016 and implemented in 2018, confines eligibility to patients medically determined to be in the dying process and recognizes only the right to refuse or withdraw futile life-sustaining interventions. Procedural safeguards include advance directive registration, tightly circumscribed surrogate decision-making when patients lack capacity, dual independent physician confirmation of terminal status, institutional ethics review, comprehensive documentation, and explicit criminal and civil immunities for clinicians who comply. The statutory architecture is built to respect patient autonomy at the natural end of life while drawing a categorical line against active euthanasia or physician-assisted suicide. Against this baseline, three common-law models illustrate distinct approaches to scope, oversight, and professional responsibility. England & Wales have advanced a Terminally Ill Adults (End of Life) Bill that limits eligibility to capacitated adults with a prognosis of six months or less, requires two independent physician assessments, mandates repeated, informed, and uncoerced requests, and builds in a cooling-off period and an external, multidisciplinary review mechanism. Conscience protections are broad, and conduct within the statutory channel would be exempted from general criminal prohibitions on assisting suicide. The Isle of Man’s Assisted Dying Bill—passed by its legislature—adopts a 12-month prognosis threshold, imposes stringent residency requirements to avoid “death tourism,” relies on two independent medical opinions (with relevant specialty expertise), uses cooling-off periods and comprehensive reporting, and emphasizes centralized oversight rather than case-by-case judicial authorization. Canada’s nationwide regime (MAID) began in 2016 with a terminal-leaning standard and, after constitutional litigation, expanded in 2021 to a dual-track model that no longer requires a reasonably foreseeable death: terminal cases follow a streamlined pathway, whereas non-terminal cases trigger heightened safeguards, including specialist involvement, exhaustive review of alternatives, and a minimum 90-day assessment period. A temporary exclusion for cases grounded solely in mental illness remains in effect pending further system readiness. Three cross-cutting comparisons emerge. First, eligibility thresholds diverge: Korea and the UK-family proposals adhere to a terminal-window paradigm (imminent death or months-based prognosis), whereas Canada recognizes intolerable, irremediable suffering even outside a terminal trajectory, subject to elevated procedural brakes. Second, oversight architectures range from primarily intra-clinical checks (Korea’s two-physician plus ethics-committee model) to layered external scrutiny (England & Wales’ expert panel) to ex post transparency and federal surveillance of caseloads (Canada). Third, all assisted-dying pathways insist on personal, contemporaneous requests; proxy initiation is barred. By contrast, Korea permits limited surrogate decisions to withdraw life support when patients lack capacity, reflecting a deliberate ethical distinction between “letting die” and “causing death.” Policy implications follow for jurisdictions contemplating reform. A cautious, terminal-only model with robust multidisciplinary review, explicit conscience clauses, mandatory reporting, and strong anti-coercion screening offers a defensible first step; alternatively, incremental strengthening of palliative care capacity and advance-directive uptake can reduce demand for life-ending interventions while honoring patient dignity. Clarifying terminology, tightening surrogate boundaries, and enhancing auditability across settings are immediate system-improvement levers. Overall, the comparative lens maps a legally and ethically salient red line: discontinuing non-beneficial treatment at life’s natural end versus intentionally advancing the time of death—each requiring distinct justifications, safeguards, and professional roles.